These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 22529801)

  • 1. Reactivation of Tuberculosis in Three Cases of Psoriasis after Initiation of Anti-TNF Therapy.
    Shaikha SA; Mansour K; Riad H
    Case Rep Dermatol; 2012 Jan; 4(1):41-6. PubMed ID: 22529801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tuberculosis reactivation risk in dermatology.
    Pescitelli L; Ricceri F; Prignano F
    J Rheumatol Suppl; 2014 May; 91():65-70. PubMed ID: 24789002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Biologics and mycobacterial diseases].
    Tsuyuguchi K; Matsumoto T
    Kekkaku; 2013 Mar; 88(3):337-53. PubMed ID: 23672175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammatory bowel disease and mycobacteria: how much can we trust isoniazid prophylaxis during antitumor necrosis factor therapy?
    Akyuz F; Cavus B; Iliaz R; Soyer OM; Ormeci A; Evirgen S; Onder S; Koksalan K; Keskin M; Karaca C; Demir K; Gulluoglu M; Cagatay T; Besisik F; Kaymakoglu S
    Eur J Gastroenterol Hepatol; 2019 Jul; 31(7):777-780. PubMed ID: 30964811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of tuberculosis reactivation during interleukin-17 inhibitor therapy for psoriasis: a systematic review.
    Fowler E; Ghamrawi RI; Ghiam N; Liao W; Wu JJ
    J Eur Acad Dermatol Venereol; 2020 Jul; 34(7):1449-1456. PubMed ID: 32012384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Restarting biologics and management of patients with flares of inflammatory rheumatic disorders or psoriasis during active tuberculosis treatment.
    Cantini F; Prignano F; Goletti D
    J Rheumatol Suppl; 2014 May; 91():78-82. PubMed ID: 24789004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of tuberculosis with anti-tumor necrosis factor-alpha therapy in patients with psoriasis and psoriatic arthritis in Indian population.
    Sarkar S; Panda S; Kim B; Raychaudhuri SK; Ghosh A; Raychaudhuri SP
    Indian J Dermatol Venereol Leprol; 2020; 86(1):1-7. PubMed ID: 31719235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice.
    Cantini F; Nannini C; Niccoli L; Iannone F; Delogu G; Garlaschi G; Sanduzzi A; Matucci A; Prignano F; Conversano M; Goletti D;
    Autoimmun Rev; 2015 Jun; 14(6):503-9. PubMed ID: 25617816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety in moderate-to-severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti-tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials.
    Puig L; Tsai TF; Bhutani T; Uy J; Ramachandran P; Song M; You Y; Gooderham M; Lebwohl M
    J Eur Acad Dermatol Venereol; 2020 Aug; 34(8):1744-1749. PubMed ID: 32289190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry.
    Tubach F; Salmon D; Ravaud P; Allanore Y; Goupille P; Bréban M; Pallot-Prades B; Pouplin S; Sacchi A; Chichemanian RM; Bretagne S; Emilie D; Lemann M; Lortholary O; Mariette X;
    Arthritis Rheum; 2009 Jul; 60(7):1884-94. PubMed ID: 19565495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Active tuberculosis in psoriasis patients treated with TNF antagonists: a French nationwide retrospective study.
    Guinard E; Bulai Livideanu C; Barthélémy H; Viguier M; Reguiai Z; Richard MA; Jullien D; Beneton N; Bara C; Vabres P; Grandvuillemin A; Marguery MC; Amelot F; Konstantinou MP; Bagheri H; Paul C;
    J Eur Acad Dermatol Venereol; 2016 Aug; 30(8):1336-41. PubMed ID: 27256154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents.
    Doherty SD; Van Voorhees A; Lebwohl MG; Korman NJ; Young MS; Hsu S; National Psoriasis Foundation
    J Am Acad Dermatol; 2008 Aug; 59(2):209-17. PubMed ID: 18485527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon-γ release assay for tuberculosis in patients with psoriasis treated with tumour necrosis factor antagonists: in vivo and in vitro analysis.
    Sauzullo I; Mengoni F; Marocco R; Potenza C; Skroza N; Tieghi T; Lichtner M; Vullo V; Mastroianni CM
    Br J Dermatol; 2013 Nov; 169(5):1133-40. PubMed ID: 23909256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. QuantiFERON TB-gold conversion rate among psoriasis patients under biologics: a 9-year retrospective study.
    Megna M; Ferrillo M; Ruggiero A; Cinelli E; Gallo L; Fabbrocini G
    Int J Dermatol; 2021 Mar; 60(3):352-357. PubMed ID: 32989759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tuberculosis in anti-TNF-α treated patients remains a problem in countries with an intermediate incidence: analysis of 25 patients matched with a control population.
    Abreu C; Magro F; Santos-Antunes J; Pilão A; Rodrigues-Pinto E; Bernardes J; Bernardo A; Magina S; Vilas-Boas F; Lopes S; Macedo G; Sarmento A
    J Crohns Colitis; 2013 Nov; 7(10):e486-92. PubMed ID: 23583099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of tuberculosis with the use of anti-TNF medications in psoriasis: incidence, screening and management.
    Kasiraman V; Atwan AA; Durojaiye OC; Kalavala M; Piguet V
    Dermatol Online J; 2014 Aug; 20(8):. PubMed ID: 25148273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of tuberculosis infection in psoriatic patients on anti-TNF therapy: report of a case series with 144 patients.
    Sánchez-Moya AI; Dauden E
    J Eur Acad Dermatol Venereol; 2011 Jun; 25(6):730-3. PubMed ID: 21564322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of tuberculosis reactivation with interleukin (IL)-17 and IL-23 inhibitors in psoriasis - time for a paradigm change.
    Nogueira M; Warren RB; Torres T
    J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):824-834. PubMed ID: 32790003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psoriasis, anti-tumor necrosis factor therapy, and tuberculosis: report of three challenging cases and literature review.
    Solovan C; Chiticariu E
    Infect Dis Ther; 2013 Jun; 2(1):59-73. PubMed ID: 25135824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The risk of tuberculosis in patients with psoriasis treated with anti-tumor necrosis factor agents.
    Ergun T; Seckin D; Baskan Bulbul E; Onsun N; Ozgen Z; Unalan P; Alpsoy E; Karakurt S
    Int J Dermatol; 2015; 54(5):594-9. PubMed ID: 25753908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.